Sobi is an international biopharmaceutical company with a 30+ year history of pioneering innovation and dedication to rare diseases. Globally we market 35 products across 67 countries, with a focus on two primary business units: Hemophilia (Europe) and Specialty Care (U.S. and Europe). Key therapeutic areas within our Specialty Care portfolio include Inflammation and Genetics & Metabolism; we market three products in four indications in these areas in North America. We have an emerging pipeline based on our expertise in genetics/metabolism, inflammation and recombinant protein engineering, with programs in Phase III, Phase II and earlier stages. Our vision is to be recognized as a global leader in providing access to innovative treatments that make a significant difference for individuals with rare diseases, and partnering in the development and commercialization of products in specialty care is a key element of our strategy.